Sermorelin research beyond the first minutes

Sermorelin mechanism of action

The sermorelin peptide is a small fragment with a surprisingly full assignment. It copies the first 29 amino acids of growth hormone-releasing hormone, or GHRH, a hormone normally made in the hypothalamus. Those 29 retain full activity at the GHRH receptor, according to the review of GHRH and its analogues. The receiving cells are in the pituitary, the gland that releases growth hormone.

The timing fascinates me. The pharmacokinetic study in healthy men reported a plasma half-life of ~10–12 minutes after intravenous administration, while growth hormone stayed elevated for about 3 hours. Half-life describes the time for the plasma level to fall by half; it says something different from how long the gland’s response lasts.

That distinction gives Sermorelin Research its subject. A fast-clearing molecule can leave a longer response, and following that response far enough produces some awkward findings. I give particular weight to the small study in which continuous exposure eventually brought a weaker GH response. It complicates the attractive idea that a signal merely needs to last longer.

What is Sermorelin, in plain words?

Sermorelin (sermorelin acetate) is GHRH(1-29)NH2 — the amidated first 29 amino acids of the 44-residue human growth hormone-releasing hormone, and the shortest fragment that keeps full activity at the GHRH receptor ^[12]. Its molecular weight is 3357.9 Da (CAS 86168-78-7; molecular formula C149H246N44O42S). It is classed as a pituitary growth-hormone secretagogue: a compound that prompts the gland to release the body's own growth hormone rather than supplying growth hormone directly.

Sermorelin was formerly FDA-approved — marketed in the United States under a brand name (NDA 020443) for evaluating and treating growth hormone deficiency and short stature in children ^[1]. It was withdrawn from the US market in 2008 for commercial reasons, not over any safety or efficacy problem, and is now compounded for individual patients when a licensed clinician issues a prescription; FDA treats sermorelin as a long-standing Category 1 bulk drug substance under the interim Section 503A policy finalized in January 2025, with that policy's conditions still applying ^[15]. "Formerly approved, now compounded" is the accurate frame — not "never approved," and not "currently approved."

That divergence is easy to miss if 2008 is read as a verdict on the molecule rather than a business decision. The endocrine and pharmacokinetic studies cataloged throughout this digest did not stop accumulating when the branded product left the market — nor did the anti-doping detection work built on top of them years later. What a prescriber draws on today is that same accumulated record, read through a compounding pharmacy rather than a discontinued NDA number. In present clinical practice, Promise Peptides prescribes compounded sermorelin for U.S. patients at mypromise.com; a clinician holding a U.S. prescribing license assesses the individual case before issuing a prescription. Some requests are declined, and the choices depend on both the patient's state and the treatment. A compounded sermorelin preparation has no FDA approval. This site's remit stays narrower than that. It holds the research record itself — logged, dated, and cited — distinct from any prescribing pathway built on top of it. The two are related documents, not one: a body of evidence that kept growing for two decades after a commercial withdrawal, and a clinical decision made against that evidence today. Keeping the record legible on its own terms, independent of how or where a reader might eventually encounter the compound, is the actual job of an evidence board.

Child growth and older men

The clearest sermorelin studies measured very concrete things. In children with growth hormone deficiency, first-year height velocity rose from about 4.1 cm/year to roughly 7–8 cm/year. In healthy older men studied for 14 days, GH and IGF-1 rose; the higher study amount brought the measured parameters toward those of young men, with fasting glucose unchanged.

IGF-1, insulin-like growth factor 1, is a hormone produced mainly by the liver in response to GH. It also feeds back on the system. I respect a result that names its measurement. Faster childhood growth and a shift in an older man’s blood tests answer different questions, and the adult wellness argument needs outcomes beyond those blood tests. The study accounts follow each experiment through to its endpoint.

Continuous exposure

The less comfortable finding came from six children receiving continuous GHRH(1-29) infusion. After an early rise, GH secretion declined by 3 to 6 months; one child’s secretion was completely suppressed. Antibodies, somatostatin changes and receptor desensitization were among the possible explanations investigated.

The short half-life looked like the obvious obstacle at first. After the infusion paper, I stopped treating the pattern of exposure as a secondary detail. A tiny study cannot settle the mechanism, but its faltering response deserves a place alongside the successful growth studies. The study amounts and durations are more interesting when that result stays in sight.

Sermorelin research products and quality

Using sermorelin for research also raises a material question: what is actually in the preparation? The critical review of peptides in sport and bodybuilding describes mislabeling and contamination in the largely unregulated supply chain. The review of approved and unapproved peptide therapies describes scarce rigorous human safety data for many unapproved uses; the sports-medicine review adds product-quality and anti-doping concerns.

The endocrine papers tell me little about the identity or purity of a particular preparation. “Sermorelin research compound” describes an intended category of work. It supplies no clinical assurance. For the other meaning of testing—the laboratory methods used in sport—the FAQ explains what those assays actually detect.